Latest Headlines

  1. Sapient Launches DynamiQ As Its Next-Generation Data Insights Engine For Drug Discovery And Development 4/30/2025

    Sapient, a leader in multi-omics data generation for biomarker discovery and clinical insight delivery, has launched the next generation of its multi-omics and real-world data (RWD) human biology database, now branded as the DynamiQ Insights Engine, which increases the speed, versatility, and depth of analyses that Sapient can perform to inform drug discovery and precision drug development strategies.

  2. [C.S Group] : Launches Antcin A-Based Veterinary Drug Initiative Across Taiwan And China 4/30/2025

    Cordyceps Sunshine Biotech Holdings Co., Ltd.【C.S Group】 announced a major milestone in veterinary drug development at the "Pharmacological Progress Conference for Taiwanofungus camphoratus Applications in the Pet Market," co-hosted with the Chinese Herbal Fungi Industry Research and Development Association (CHFIRDA).

  3. Cytiva And Asimov Collaborate On Next Generation Cell Line Design And Process Development 4/29/2025

    Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, is collaborating with Cytiva, a global life sciences leader, to provide customers with an integrated offering for optimized biologics production.

  4. Pointing The Way Towards The Future Of Drug Development 4/28/2025

    Can AI and automation shorten the time it takes to develop new drugs? Ola Spjuth combines his academic expertise in data-driven drug development with entrepreneurship to help the pharmaceutical industry capitalise on the potential of new technologies.

  5. Silo Pharma Expands Intellectual Property Portfolio With Patent Application For Exclusively Licensed Alzheimer's Drug 4/28/2025

    Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a patent application with the U.S. Patent and Trademark Office (USPTO) focused on the neurology drug SPC-14, an intranasal compound for the treatment of Alzheimer’s disease (AD) exclusively licensed to Silo Pharma from Columbia University.

  6. Intellomx Launches Swarm-Based AI Platform To Accelerate And De-Risk Novel Target And Drug Discovery 4/28/2025

    Intellomx (Intelligent OMICS Ltd) today announced the deployment of Intellomx Pilot, delivering rapid identification of novel drugs arising from its existing precision therapeutic target identification capability, offering pharmaceutical innovators a powerful tool to streamline and de-risk the drug discovery process.

  7. Tempus Introduces Loop, An AI-Powered Target Discovery And Validation Platform 4/28/2025

    Tempus AI, Inc., a technology company leading the adoption of AI to advance precision medicine and patient care, today announced Tempus Loop, a new oncology-focused platform for target discovery and validation.

  8. Eton Pharmaceuticals Announces Submission Of NDA For ET-600 (Desmopressin Oral Solution) 4/28/2025

    Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ET-600, Eton’s proprietary, patented oral solution of desmopressin under development for the treatment of central diabetes insipidus.

  9. Thermo Fisher Scientific Leverages Integrated Solutions To Accelerate The Development Of Biologic Therapeutics 4/28/2025

    Thermo Fisher Scientific, the world leader in serving science, is employing an enhanced platform technology and a new CHO K-1 cell line that can reduce timelines to Investigational New Drug (IND) filing from 13 to nine months, helping biotech and pharmaceutical companies overcome logistical complexities within pre-clinical biologic drug development.

  10. Innorna Announces FDA Rare Pediatric Disease And Orphan Drug Designations Granted To IN013 For Treatment Of Wilson Disease 4/27/2025

    Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD).